$GALT

Galectin Therapeutics (GALT) will present data on belapectin for MASH cirrhosis at AASLD Liver Meeting 2026. The company submitted a Phase 3 trial protocol to the FDA. Presentations include risk analyses from NAVIGATE and GT-026 trials, highlighting noninvasive prediction of variceal development. Galectin aims to advance belapectin as a treatment for MASH cirrhosis and portal hypertension.

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reporte

Galvanize Therapeutics, Inc. said it completed the first commercial procedures using its FDA-cleared Aliya EX pulsed electric field system, following 510(k) clearance in May 2026. The first percutaneous and endoscopic procedures were performed at Duke and Eisenhower Health. Aliya EX targets up to 2x larger ablation diameter and up to 7x ablation volume.

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximatel

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.

GALT Aerospace, backed by Godspeed Capital, said it acquired North Star Scientific Corporation (NSS), a Hawaii-based defense electronics maker. NSS designs high-power RF amplifiers, transmitters, antennas and electronically scanned arrays for C2, sensing and AEW&C, serving U.S. Air Force and Navy programs. GALT said the deal expands its C3ISR portfolio and program base; NSS is GALT’s first acquisition.

Boundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.

NORCROSS, Ga., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc. ( NASDAQ: GALT ) , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.